dr. Boštjan Martinc
št.: 60360

Boštjan Martinc, PharmD, PhD Consultant Clinical Pharmacist | Scientific Associate I am a consultant clinical pharmacist and scientific associate at the University Rehabilitation Institute of the Republic of Slovenia – URI Soča. I provide advanced clinical pharmacotherapy services at the secondary care level, including an outpatient clinical pharmacist consultation clinic focused on structured medication review, polypharmacy optimisation, deprescribing, and complex pharmacotherapy management, particularly in patients with multimorbidity and chronic pain. I obtained my PhD in Biomedical Sciences (Pharmacy track) from the Faculty of Pharmacy, University of Ljubljana in 2015. My doctoral research explored antiepileptic pharmacotherapy monitoring and oxidative stress biomarkers, integrating clinical pharmacology with translational redox science. In 2014, I completed specialist training in Clinical Pharmacy, with a thesis evaluating the impact of pharmacist-led interventions on glycaemic control in type 2 diabetes. I graduated in Pharmacy in 2006. Throughout my career, I have held leadership and senior clinical roles in public pharmacy institutions, including Head Pharmacist, Deputy Head Pharmacist, Consultant Pharmacist, and Assistant Director. Since 2018, I have actively practised as a consultant pharmacist within primary care health centres, implementing structured pharmaceutical care models. At the national level, I served as National Coordinator for Pharmaceutical Care in Diabetes, contributing to the Slovenian National Diabetes Programme and Ministry of Health working groups. I have organised national training workshops for clinical pharmacy moderators and participated in strategic health literacy and implementation initiatives. Academically, I was appointed Assistant in Biopharmaceutics and Pharmacokinetics at the Faculty of Pharmacy, University of Ljubljana. My research interests include polypharmacy optimisation, pharmacovigilance-informed deprescribing frameworks, medication safety, oxidative stress biomarkers in diabetes, and translational clinical pharmacology. I focus on bridging regulatory signal detection, mechanistic pharmacology, and structured benefit–harm reassessment into clinically implementable models. My professional mission is to advance evidence-based, system-integrated pharmaceutical care that improves medication safety, optimises therapeutic outcomes, and strengthens interdisciplinary collaboration across care levels.